Back to search

284 result(s):

PATIENT EXPERIENCES AT MONTH 6 AFTER INITIATION OF CABOTEGRAVIR▼ LONG-ACTING (CAB LA) FOR PREP IN THE FIRST MALE GENDER CONCORDANT IMPLEMENTATION SCIENCE TRIAL (PILLAR) IN THE US

CABOTEGRAVIR▼ LONG-ACTING FOR PRE-EXPOSURE PROPHYLAXIS (PREP): REAL WORLD DATA ON ON-TIME DOSING, HIV TESTING AND HIV ACQUISITION FROM THE OPERA COHORT

IMPROVED TESTING FOR CHRONIC DISEASE AMONG LONG-ACTING INJECTABLE VERSUS DAILY ORAL ANTIRETROVIRAL THERAPY USERS IN THE OPERA COHORT

OPPORTUNITIES FOR PREP AWARENESS AND ENGAGEMENT: A SURVEY AMONG HEALTHCARE-SEEKING CISGENDER WOMEN IN THE US

SOCIAL DETERMINANTS OF HEALTH AND SIDE EFFECTS SIGNIFICANTLY PREDICT PRE-EXPOSURE PROPHYLAXIS (PREP) PREFERENCES FOR EVERY 2 MONTH LONG-ACTING INJECTABLE VS. DAILY ORAL PREP AMONG CISGENDER WOMEN IN THE UNITED STATES AND THE DOMINICAN REPUBLIC

Can’t find what you’re looking for or would like to discuss our data in person? Contact your MSL

Contact us

NP-GBL-HVX-WCNT-220014 September 2024

Report an adverse event

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221441.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.